StockNews.AI
CODX
StockNews.AI
159 days

Co-Diagnostics, Inc. Announces Fourth Quarter and Full Year 2024 Earnings Release Date and Webcast

1. Co-Diagnostics will release Q4 and 2024 results on March 27, 2025. 2. A conference call will follow the financial results announcement. 3. Management will discuss results, including CEO and CFO participation. 4. Co-Diagnostics specializes in molecular diagnostic tests and unique technologies.

Earnings
-3.14%Current Return
VS
+0.78%S&P 500
$0.503/13 09:35 AM EDTEvent Start
$0.484303/14 04:00 PM EDTLatest Updated
4m saved
Insight
Article

FAQ

Why Neutral?

Upcoming earnings reports often result in volatility, but no immediate catalysts are present. Historical trends show mixed market reactions to earnings in similar companies.

How important is it?

Earnings announcements can impact investor sentiment and future forecasts directly. The uniqueness of CODX’s technology may provide growth potential discussed in the earnings call.

Why Short Term?

The announcement impacts trading around the earnings date. Similar past earnings have typically created short-lived stock movements.

Related Companies

NASDAQ: CODX
, /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today it will release its fourth quarter and full year 2024 results on Thursday, March 27, 2025, after the market close. The Company will also host a conference call and webcast on the same day at 4:30 p.m. ET to discuss its financial results with analysts.  Management on the call will include Dwight Egan, Chief Executive Officer, Brian Brown, Chief Financial Officer, and Andrew Benson, Head of Investor Relations. The conference call and webcast will be available via: Webcast: ir.codiagnostics.com on the Events & Webcasts page Conference Call: 844-481-2661 (domestic) or 412-317-0652 (international) If you are unable to participate during the live webcast, the call will be recorded and later made available on the Company's website. About Co-Diagnostics, Inc.Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets state-of-the-art diagnostics technologies. The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR at-home and point-of-care platform and to identify genetic markers for use in applications other than infectious disease. SOURCE Co-Diagnostics WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In

Related News